Curaleaf Q2 Revenue Reaches $340M as International Sales Surge 26% and Margins Hold at 50%

summarizeSummary

Curaleaf reported Q2 2026 revenue of $340 million, up 10% year-over-year, with international revenue surging 26% to $51 million. Gross margin held at 50%, net income was $12 million, and adjusted EBITDA reached $70 million.

check_boxKey Events · Earnings and Guidance · CURLF

• Revenue Growth Accelerates

  Q2 net revenue of $340.1 million, a 10% increase year-over-year, with domestic revenue up 7% and international revenue up 26% to $51.4 million.

• Profitability Improves

  Net income from continuing operations was $12.5 million, or $0.05 per share, compared to a net loss of $48.1 million in Q2 2025. Adjusted EBITDA was $70.1 million, a 20.6% margin.

• Strategic Milestones Achieved

  Completed the buyout of the remaining 45% of Four20 Pharma, applied to register all medical locations with the DEA, and appointed two new board members.

• Balance Sheet and Cash Flow

  Ended the quarter with $107 million in cash and $611.5 million in debt. Free cash flow from continuing operations was $17.4 million for the first half of 2026.

auto_awesomeAnalysis · CURLF · Life Sciences

A solid quarter for Curaleaf featured 10% revenue growth, fueled by a 26% surge in international sales. Gross margins held steady at 50%, and the company swung to a net profit of $12 million. The balance sheet carries $107 million in cash against $611 million in debt, while strategic moves—including the Four20 Pharma buyout and DEA registration applications—continue to advance. This quarter reinforces the narrative that Curaleaf's domestic business has stabilized and international expansion is accelerating, though the adjusted EBITDA margin dipped slightly year-over-year.